Buradasınız

Anasayfa » Content

Primer FSGS Hastalarında İmmunfl oresan Boyamanın Önemi

The Importance of Immunofl uorescence Staining in Patients with Primary FSGS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2014
DOI: 
10.5262/tndt.2014.1001.10

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
OBJECTIVE: In patients with primary FSGS, the degree of proteinuria, serum creatinine levels, histologic fi ndings, and response to therapy are important prognostic factors. In this study, the importance of immunofl uorescence staining on response to therapy and progression to chronic renal failure were retrospectively evaluated in patients with primary FSGS. MATERIAL and METHODS: Pathologic, clinical and laboratory features, follow-up outpatient/ clinical records of 60 patients with a pathologic diagnosis of FSGS by renal biopsy in GATA Nephrology Clinic between 2000-2012 were retrospectively evaluated. RESULTS: In this retrospective study conducted on the effect of the immunofl uorescence staining on renal surveillance in patients with primary FSGS, accumulation of fi brin was found to have a relationship with renal surveillance. Progression was more rapid in patients with fi brin accumulation, but this result did not reach a statistical signifi cance. No statistical relationship was found between other parameters and renal surveillance. For complete understanding of the possible negative impact of the accumulation of fi brin, further studies on larger patient groups are needed. CONCLUSION: The studies examining many parameters are in advance in order to estimate response to treatment in patients with primary FSGS. New parameters to predict renal surveillance is still needed while steroid or other immunosuppressives are been initiating in patients presenting with nephrotic range proteinuria.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Primer FSGS hastalarında, proteinürinin derecesi, serum kreatinin düzeyi, histolojik bulgular ve tedaviye yanıt önemli prognostik faktörlerdir. Bu çalışmada, primer FSGS hastalarında immünfl oresan boyamanın tedaviye yanıtta ve kronik böbrek hastalığına progresyonda önemi retrospektif olarak değerlendirilmiştir. GEREÇ ve YÖNTEMLER: GATA Nefroloji kliniği tarafından 2000-2012 yılları arasında takip edilen 60 primer FSGS olgusunun patolojik, klinik ve laboratuvar özellikleri retrospektif olarak değerlendirilmiştir. BULGULAR: Bu retrospektif çalışmada, immünfl oresan boyamanın renal fonksiyonlarla ilişkisi değerlendirilmiştir. Fibrin dışında diğer parametrelerle bir ilişki kurulamamıştır. Fibrin birikimi olan olgular daha progresif seyretmiş fakat bu istatistiksel bir değere ulaşmamıştır. Fibrin birikiminin negatif ilişkisini anlamak için daha fazla hasta içeren çalışmalara ihtiyaç vardır. SONUÇ: Primer FSGS olgularında tedaviye yanıtı belirlemek için birçok parametre çalışmalarda değerlendirilmiştir. Nefrotik düzeyde proteinüri ile seyreden hastalara steroid veya diğer immünsupresif tedavilere başlama kararı verirken yeni parametrelere ihtiyaç vardır.
FULL TEXT (PDF): 
PDF icon arastirmax-primer-fsgs-hastalarinda-immunfl-oresan-boyamanin-onemi.pdf
  • 1
51
55
  • Turkish

REFERENCES

References: 

1. Southwest Pediatric Nephrology Study Group: Focal segmental
glomerulosclerosis in children with idiopathic nephrotic syndrome.
Kidney Int 1985;27:442-449
2. Haas M, Meehan SM, Karrison TG, Spargo BH: Changing etiologies
of unexplained adult nephrotic syndrome: A comparison of renal
biopsy fi ndings from 1976-1979 and 1995-1997. Am J Kidney Dis
1997; 30: 621-631
3. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI,
Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS,
Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM,
Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H,
Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal
segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-11844. Kitiyakara C, Eggers P, Kopp JB: Twenty-one-year trend in ESRD
due to focal segmental glomerulosclerosis in the United States. Am
J Kidney Dis 2004; 44: 815-825
5. D’Agati V: The many masks of focal segmental glomerulosclerosis.
Kidney Int 1994; 46: 1223-1241
6. Wagrowska-Danilewicz M, Danilewicz M: Synaptopodin
immunoexpression in steroid-responsive and steroid-resistant
minimal change disease and focal segmental glomerulosclerosis.
Nefrologia 2007; 27: 710-715
7. Praga M, Morales E, Herrero JC, Pérez Campos A, Domínguez-Gil
B, Alegre R, Vara J, Martínez MA: Absence of hypoalbuminemia
despite massive proteinuria in focal segmental glomerulosclerosis
secondary to hyperfi ltration. Am J Kidney Dis 1999; 33: 52-58
8. D’Agati V: Pathologic classifi cation of focal segmental
glomerulosclerosis. Semin Nephrol 2003; 23: 117-134
9. Rennke HG, Klein PS: Pathogenesis and signifi cance of nonprimary
focal and segmental glomerulosclerosis. Am J Kidney Dis 1989; 13:
443-456
10. D’Agati VD, Fogo AB, Bruijn JA, Jennette JC: Pathologic
classifi cation of focal segmental glomerulosclerosis: A working
proposal. Am J Kidney Dis 2004; 43: 368-382
11. Deegens JK, Steenbergen EJ, Wetzels JF: Review on diagnosis and
treatment of focal segmental glomerulosclerosis. Neth J Med 2008;
66: 3-12
12. Abrantes MM, Cardoso LS, Lima EM, Silva JM, Diniz JS, Bambirra
EA, Oliveira EA: Clinical course of 110 children and adolescents
with primary focal segmental glomerulosclerosis. Pediatr Nephrol
2006; 21: 482-489
13. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC;
Toronto Glomerulonephritis Registry Group: Focal and segmental
glomerulosclerosis: Defi nition and relevance of a partial remission.
J Am Soc Nephrol 2005; 16: 1061-1068
14. Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE,
Falk RJ, Jennette JC: Clinical and pathologic characteristics of focal
segmental glomerulosclerosis pathologic variants. Kidney Int 2006;
69: 920-926
15. Rydel JJ, Korbet SM, Borok RZ and Schwartz MM: Focal segmental
glomerular sclerosis in adults: presentation, course, and response to
treatment. Am J Kidney Dis 1995; 25: 534-542
16. Ponticelli C, Rizzoni G, Edefonti A, Rivolta E, Rinaldi S, Ghio
L, Lusvarghi E, Gusmano R, Locatelli F: A randomized trial of
cyclosporine in steroid resistant idiopathic nephrotic syndrome.
Kidney Int 1993; 43: 1377-1384
17. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy
WE, Maxwell DR, Kunis CL: A randomized trial of cyclosporine in
patients with steroid-resistant focal segmental glomerulosclerosis.
Kidney Int 1999; 56: 2220-222618. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ: Focal segmental
glomerulosclerosis in nephrotic adults: Presentation, prognosis, and
response to therapy of the histologic variants. J Am Soc Nephrol
2004; 15: 2169-2177
19. Korbet SM, Schwartz MM, Lewis EJ: Primary focal segmental
glomerulosclerosis: Clinical course and response to therapy. Am J
Kidney Dis 1994; 23: 773-783
20. Korbet SM. Primary focal segmental glomerulosclerosis. In: Brady
R, Wilcox C (eds), Therapy in Nephrology and Hypertension: A
companion to Brenner and Rector’s the 248 Kidney. Philadelphia:
Saunders, 2003: 223-236
21. Bazzi C, Petrini C, Rizza V, Napodano P, Paparella M, Arrigo G,
Pisano L, D’Amico G: Fractional excretion of IgG predicts renal
outcome and response to therapy in primary focal segmental
glomerulosclerosis: A pilot study. Am J Kidney Dis 2003; 41: 328-
335
22. Deegens JK, Wetzels JF: Fractional excretion of high- and lowmolecular
weight proteins and outcome in primary focal segmental
glomerulosclerosis. Clin Nephrol 2007; 68: 201-208
23. Roja JR, Pérez M, Hurtado A, Asato C: Factors predicting for renal
survival in primary focal segmental glomerulosclerosis. Nefrología
2008; 28: 439-446
24. Stirling CM, Mathieson P, Boulton-Jones JM, Feehally J, Jayne D,
Murray HM, Adu D: Treatment and outcome of adult patients with
primary focal segmental glomerulosclerosis in fi ve UK renal units.
QJM 2005; 98: 443-449
25. Taheri D, Chehrei A, Samanianpour P, Sadrarhami S, Keshteli AH,
Shahidi S: The predictive role of histopathological fi ndings in renal
insuffi ciency and complete remission in a sample of Iranian adults
with primary focal segmental glomerulosclerosis. J Res Med Sci
2010; 15: 14-19
26. Vlasić-Matas J, Glavina Durdov M, Capkun V, Galesić K: Prognostic
value of clinical, laboratory, and morphological factors in patients
with primary focal segmental glomerulosclerosis - Distribution of
pathological variants in the Croatian population. Med Sci Monit
2009; 15: 121-128

Thank you for copying data from http://www.arastirmax.com